hit counter

Kappa Opioid Receptors (KORs) vs. Depression & Stress-Related Brain Region Activation (2023 Study)

Depression, a complex and multifaceted disorder, challenges both individuals and society with its pervasive effects and the limitations of current treatments. Recent research has spotlighted the opioid system, specifically the kappa opioid receptor (KOR), as a potential target for innovative treatments. This focus is grounded in findings that KOR activation influences stress hormone levels and …

Read more

New Antidepressant ALKS 5461 Trials: 2016 Expected Availability

ALKS-5461 is a new drug that is being developed by the company Alkermes as an alternative to SSRI’s for the treatment of depression. ALKS-5461 (its trial name) is a combination of both buprenorphine (suboxone) and samidorphan, and is regarded as a non-addictive opioid modulator and antidepressant. It is currently being developed specifically as an antidepressant …

Read more